“As clinical data reinforces the value of multi-drug protocols for the treatment of refractory conditions such as cancer and HIV, drug developers and pharmaceutical strategists are taking a harder look at technology for delivering two or more drugs in the same dosage form factor at different, and sometimes variable, rate profiles,” explains George Perros, Greystone Managing Director. “The availability of multiple drugs in a single delivery system simplifies administration and improves compliance, further benefiting outcomes.”
While interest in multi-drug delivery systems is growing across several therapeutic applications, an area of significant potential is in therapeutic drug combinations for HIV, a disease where the religious administration of multiple drugs is deemed critical to therapeutic outcomes. Chemotherapeutic ‘cocktails’ for various cancers are also strong candidates for multi-drug delivery technology.
These survey findings are contained in a new and comprehensive report: Multi-Drug Delivery Systems: Emerging Therapeutics and Opportunities The report contains a comprehensive assessment of multi-drug delivery technology, and provides an assessment of current and probably future multi-drug combination products, profiles of market participants, industry data and forecasts, and detailed analysis of regulatory and market factors. Organized and written to be of maximum value to pharmaceutical industry decision makers, delivery technology developers, and industry strategists, the report provides a detailed analysis of the growing potential for multi-drug delivery systems in disease therapeutics.
More information is available at www.greystoneassociates.org .
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
www.greystoneassociates.org Source: Greystone Associates
For more information:
Last updated on: 27/08/2010